Engaging European society at the forefront of cancer research and care: How discussions at the 5^th Gago Conference on European Science policy led to the Heidelberg Manifesto

Michael Baumann^{1

2}, Julio Celis^{2

3}, Ulrik Ringborg^{2

4}, Manuel Heitor^{2

5}, Anton Berns^{2

6}, Tit Albreht^{7

8}, Jeliazko Arabadjiev^{9

10}, Michael Boutros^{2

11

12}, Mario Brandenburg¹³, Helena Canhao¹⁴, Fatima Carneiro^{2

15

16

17}, Christine Chomienne¹⁸, Francesco De Lorenzo^{2

19}, Alexander M M Eggermont^{2

20

21

22}, Angel Font²³, Elena Garralda^{24

25}, Margarida Goulart²⁶, Rui Henrique^{27

28}, Mark Lawler^{2

29}, Lena Maier-Hein³⁰, Francoise Meunier^{2

31}, Simon Oberst³², Pedro Oliveira³³, Maria Papatriantafyllou³⁴, Joachim Schüz^{2

35}, Eric Solary^{2

36

37}, Alfonso Valencia^{38

39}, Rosalia Vargas⁴⁰, Elisabete Weiderpass^{2

35}, Nils Wilking⁴¹

Affiliations

¹ German Cancer Research Center (DKFZ), Heidelberg, Germany.
² European Academy of Cancer Sciences, Stockholm, Sweden.
³ Danish Cancer Society Research Center, Copenhagen, Denmark.
⁴ Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden.
⁵ Center for Innovation, Technology and Policy Research, IN+ @ IS Técnico, University of Lisbon, Portugal.
⁶ The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁷ National Institute of Public Health of Slovenia, Ljubljana, Slovenia.
⁸ Faculty of Medicine, University of Ljubljana, Slovenia.
⁹ Clinic of Medical Oncology, University Hospital Acibadem City Clinic Tokuda, Sofia, Bulgaria.
¹⁰ Bulgarian Scientific Society of Immuno-oncology, and MoC Board, Sofia, Bulgaria.
¹¹ Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ) and Heidelberg University, Germany.
¹² DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany.
¹³ Federal Ministry of Education and Research (BMBF), Berlin, Germany.
¹⁴ Comprehensive Health Research Center (CHRC), NOVA Medical School, Universidade Nova de Lisboa, Portugal.
¹⁵ Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup), Portugal.
¹⁶ Instituto de Investigação e Inovação em Saúde (i3S), Faculdade de Medicina da Universidade do Porto (FMUP), Portugal.
¹⁷ Centro Hospitalar Universitário de São João (CHUSJ), Porto, Portugal.
¹⁸ Université de Paris, France.
¹⁹ European Cancer Patient Coalition, Brussels, Belgium.
²⁰ Department Cancer Medicine, CSO Princess Máxima Centre Pediatric Oncology, University Medical Center Utrecht, The Netherlands.
²¹ Board of the Comprehensive Cancer Center Munich, Technical University Munich, Germany.
²² Ludwig Maximiliaan University, Munich, Germany.
²³ La Caixa Foundation, Barcelona, Spain.
²⁴ Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
²⁵ Cancer Core Europe, Amsterdam, The Netherlands.
²⁶ Joint Research Center, European Commission, Brussels, Belgium.
²⁷ Department of Pathology & Cancer Biology & Epigenetics Group - Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (P.CCC Raquel Seruca), Portugal.
²⁸ Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Portugal.
²⁹ FRCPath Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, UK.
³⁰ Intelligent Medical Systems (IMSY), German Cancer Research Center (DKFZ), Heidelberg, Germany.
³¹ Belgian Royal Academy of Medicine, Brussels, Belgium.
³² Quality and Accreditation, Organisation of European Cancer Institutes, Brussels, Belgium.
³³ Nova School of Business and Economics, Copenhagen Business School & Patient Innovation, Frederiksberg, Denmark.
³⁴ Molecular Oncology, FEBS Press, Cambridge, UK.
³⁵ International Agency for Research on Cancer (IARC/WHO), Lyon, France.
³⁶ INSERM, U1287 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
³⁷ Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
³⁸ Barcelona Supercomputing Center (BSC), Barcelona, Spain.
³⁹ ICREA, Barcelona, Spain.
⁴⁰ Ciencia Viva, Lisbon, Portugal.
⁴¹ Karolinska Institutet, Stockholm, Sweden.

PMID: 36938773
PMCID: PMC10257409
DOI: 10.1002/1878-0261.13423

Engaging European society at the forefront of cancer research and care: How discussions at the 5^th Gago Conference on European Science policy led to the Heidelberg Manifesto

Michael Baumann et al. Mol Oncol. 2023 Jun.

. 2023 Jun;17(6):925-945.

doi: 10.1002/1878-0261.13423. Epub 2023 May 5.

Authors

Affiliations

¹ German Cancer Research Center (DKFZ), Heidelberg, Germany.
² European Academy of Cancer Sciences, Stockholm, Sweden.
³ Danish Cancer Society Research Center, Copenhagen, Denmark.
⁴ Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden.
⁵ Center for Innovation, Technology and Policy Research, IN+ @ IS Técnico, University of Lisbon, Portugal.
⁶ The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁷ National Institute of Public Health of Slovenia, Ljubljana, Slovenia.
⁸ Faculty of Medicine, University of Ljubljana, Slovenia.
⁹ Clinic of Medical Oncology, University Hospital Acibadem City Clinic Tokuda, Sofia, Bulgaria.
¹⁰ Bulgarian Scientific Society of Immuno-oncology, and MoC Board, Sofia, Bulgaria.
¹¹ Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ) and Heidelberg University, Germany.
¹² DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany.
¹³ Federal Ministry of Education and Research (BMBF), Berlin, Germany.
¹⁴ Comprehensive Health Research Center (CHRC), NOVA Medical School, Universidade Nova de Lisboa, Portugal.
¹⁵ Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup), Portugal.
¹⁶ Instituto de Investigação e Inovação em Saúde (i3S), Faculdade de Medicina da Universidade do Porto (FMUP), Portugal.
¹⁷ Centro Hospitalar Universitário de São João (CHUSJ), Porto, Portugal.
¹⁸ Université de Paris, France.
¹⁹ European Cancer Patient Coalition, Brussels, Belgium.
²⁰ Department Cancer Medicine, CSO Princess Máxima Centre Pediatric Oncology, University Medical Center Utrecht, The Netherlands.
²¹ Board of the Comprehensive Cancer Center Munich, Technical University Munich, Germany.
²² Ludwig Maximiliaan University, Munich, Germany.
²³ La Caixa Foundation, Barcelona, Spain.
²⁴ Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
²⁵ Cancer Core Europe, Amsterdam, The Netherlands.
²⁶ Joint Research Center, European Commission, Brussels, Belgium.
²⁷ Department of Pathology & Cancer Biology & Epigenetics Group - Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (P.CCC Raquel Seruca), Portugal.
²⁸ Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Portugal.
²⁹ FRCPath Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, UK.
³⁰ Intelligent Medical Systems (IMSY), German Cancer Research Center (DKFZ), Heidelberg, Germany.
³¹ Belgian Royal Academy of Medicine, Brussels, Belgium.
³² Quality and Accreditation, Organisation of European Cancer Institutes, Brussels, Belgium.
³³ Nova School of Business and Economics, Copenhagen Business School & Patient Innovation, Frederiksberg, Denmark.
³⁴ Molecular Oncology, FEBS Press, Cambridge, UK.
³⁵ International Agency for Research on Cancer (IARC/WHO), Lyon, France.
³⁶ INSERM, U1287 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
³⁷ Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
³⁸ Barcelona Supercomputing Center (BSC), Barcelona, Spain.
³⁹ ICREA, Barcelona, Spain.
⁴⁰ Ciencia Viva, Lisbon, Portugal.
⁴¹ Karolinska Institutet, Stockholm, Sweden.

PMID: 36938773
PMCID: PMC10257409
DOI: 10.1002/1878-0261.13423

Abstract

European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5^th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.

Keywords: Mission on Cancer; cancer prevention; cancer research; policy.

PubMed Disclaimer

Conflict of interest statement

Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Elena Garralda reports consultant honoraria from Roche/Genentech, F. Hoffmann‐La Roche, Ellipses Pharma, Neomed Therapeutics Inc., Boehringer Ingelheim‐Janssen Global Services, AstraZeneca, SeaGen, TFS‐Alkermes, Thermo Fisher, Brristol‐Mayers Squibb, MabDDiscovery, Anaveon, F‐Star Therapeutics, Hengrui, Sanofi; research funding from Novartis/Roche, Thermo Fisher, AstraZeneca, Taihho, BeiGene; is a principal investigator/subinvestigator of clinical trials for Adaptimmune LLC, Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Bicycletx Ltd, BioInvent International AB, Biontech SE, Biontech Small Molecules Gmbh, Boehringer Ingelhem International Gmbh, Catalym Gmbh, Cyclacel Biopharmaceuticals, Cytovation AS, Cytomx, Dot Therapeutics, F.Hoffmann La Roche Ltd, F‐Star Beta Limited, Genentech Inc, Genmab B.V., Hifibio Therapeutics, Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Incyte Corporation, Incyte Europe Sàrl, Janssen‐Cilag International NV, Janssen‐Cilag SA, Laboratorios Servier SL, Medimmune Llc, Merck & Co, Inc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Pfizer Slu, Relay Therapeutics, Replimmune, Ribon Therapeutics, Ryvu Therapeutics SA, Seattle Genetics Inc, Sotio as, Sqz Biotechnologies, Symphogen A/S, Taiho Pharma Usa Inc, T‐Knife Gmbh. Mark Lawler declares honoraria unrelated to this work from Bayer, Carnall Farrar, EMD Serono, Novartis, Pfizer and Roche.

References

1. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47. - PMC - PubMed
1. Solary E, Abou‐Zeid N, Calvo F. Ageing and cancer: a research gap to fill. Mol Oncol. 2022;16(18):3220–37. - PMC - PubMed
1. Dal Maso L, Santoro A, Iannelli E, de Paoli P, Minoia C, Pinto M, et al. Cancer cure and consequences on survivorship care: position paper from the Italian Alliance Against Cancer (ACC) Survivorship Care Working Group. Cancer Manag Res. 2022;14:3105–18. - PMC - PubMed
1. Celis JE, Pavalkis D. A mission‐oriented approach to cancer in Europe: a joint mission/vision 2030. Mol Oncol. 2017;11(12):1661–72. - PMC - PubMed
1. Adami HO, Berns A, Celis JE, de Vries E, Eggermont A, Harris A, et al. European Academy of Cancer Sciences – position paper. Mol Oncol. 2018;12(11):1829–37. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Engaging European society at the forefront of cancer research and care: How discussions at the 5^th Gago Conference on European Science policy led to the Heidelberg Manifesto

Affiliations

Engaging European society at the forefront of cancer research and care: How discussions at the 5^th Gago Conference on European Science policy led to the Heidelberg Manifesto

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous